Article
Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup.
Drug metabolism and personalized therapy - 8 Jul 2021
Al-Rubaish Abdullah M, Al-Muhanna Fahad A, Alshehri Abdullah M, Alsulaiman Abdulla A, Alabdulali Majed M, Alkhamis Fahad, Alamri Abdulallh S, Alali Rudaynah A, Akhtar Mohammed S, Cyrus Cyril, Claassens Daniel M F, Asselbergs Folkert W, Al-Ali Amein K
Abstract excerpt
OBJECTIVES: To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its bioactivation is catalyzed by cytochrome P450 (CYP)2C19. The main objective of this work was to determine the prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and assess the suitability of using genotyping to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.